Loading…
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $45M | $-7M | $-10M | $-12M | -27.5% | -6.1% | - |
| 2024 | $48M | $5M | $-0M | $27M | 7.4% | 123.7% | - |
| 2023 | $21M | $-12M | $-16M | $-17M | 138.1% | 1284.5% | - |
| 2022 | $2M | $-23M | $-24M | $-18M | 923.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 1.53 | 21.25 | 47.54 | 44.64 |
| Cost Of Revenue | 0.09 | 1.26 | 3.18 | 3.76 |
| Gross Profit | 1.45 | 19.99 | 44.35 | 40.88 |
| Operating Expense | 24.19 | 33.05 | 41.88 | 47.22 |
| Operating Income | -22.74 | -13.06 | 2.48 | -6.35 |
| EBITDA | -22.59 | -12.36 | 4.80 | -7.45 |
| EBIT | -22.74 | -12.65 | 4 | -7.55 |
| Pretax Income | -23.71 | -16.05 | -0.07 | -9.63 |
| Tax Provision | 0 | 0 | 0.36 | 0.11 |
| Net Income | -23.71 | -16.05 | -0.44 | -9.74 |
| Net Income Common Stockholders | -23.71 | -16.05 | -0.44 | -9.74 |
| Total Expenses | 24.27 | 34.31 | 45.06 | 50.99 |
| Interest Expense | 0.98 | 3.39 | 4.07 | 2.08 |
| Interest Income | 0.20 | 0.44 | 1.68 | 0.79 |
| Research And Development | 3.53 | 0.06 | 0.31 | 0.25 |
| Selling General And Administration | 20.51 | 32.71 | 41.48 | 46.91 |
| Normalized EBITDA | -22.39 | -12.33 | 4.96 | -5.46 |
| Normalized Income | -23.52 | -16.01 | -0.31 | -8.16 |
| Basic EPS | -0.90 | -0.60 | 0 | -0.34 |
| Diluted EPS | -0.90 | -0.60 | 0 | -0.34 |
| Tax Effect Of Unusual Items | 0 | 0 | -0.03 | -0.42 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Total Unusual Items | -0.19 | -0.03 | -0.16 | -2 |
| Total Unusual Items Excluding Goodwill | -0.19 | -0.03 | -0.16 | -2 |
| Net Income From Continuing Operation Net Minority Interest | -23.71 | -16.05 | -0.44 | -9.74 |
| Reconciled Depreciation | 0.15 | 0 | 0.80 | 0.10 |
| Reconciled Cost Of Revenue | 0.09 | 1.55 | 2.47 | 3.73 |
| Net Interest Income | -0.78 | -2.95 | -2.39 | -1.29 |
| Net Income From Continuing And Discontinued Operation | -23.71 | -16.05 | -0.44 | -9.74 |
| Total Operating Income As Reported | -22.59 | -12.77 | 2.57 | -6.28 |
| Diluted Average Shares | 26.27 | 26.57 | 27.29 | 28.58 |
| Basic Average Shares | 26.27 | 26.57 | 27.29 | 28.58 |
| Diluted NI Availto Com Stockholders | -23.71 | -16.05 | -0.44 | -9.74 |
| Net Income Including Noncontrolling Interests | -23.71 | -16.05 | -0.44 | -9.74 |
| Net Income Continuous Operations | -23.71 | -16.05 | -0.44 | -9.74 |
| Other Income Expense | -0.19 | -0.03 | -0.16 | -2 |
| Special Income Charges | 0 | 0 | 0 | -2.02 |
| Other Special Charges | 0 | 0 | 0 | 2.02 |
| Gain On Sale Of Security | -0.19 | -0.03 | -0.16 | 0.03 |
| Net Non Operating Interest Income Expense | -0.78 | -2.95 | -2.39 | -1.29 |
| Total Other Finance Cost | 0.15 | 0.29 | 0.09 | 0 |
| Interest Expense Non Operating | 0.98 | 3.39 | 4.07 | 2.08 |
| Interest Income Non Operating | 0.20 | 0.44 | 1.68 | 0.79 |
| Depreciation Amortization Depletion Income Statement | 0.15 | 0.29 | 0.09 | 0.06 |
| Depreciation And Amortization In Income Statement | 0.15 | 0.29 | 0.09 | 0.06 |
| Amortization | 0.15 | 0.29 | 0.09 | 0.06 |
| Amortization Of Intangibles Income Statement | 0.15 | 0.29 | 0.09 | 0.06 |
| Selling And Marketing Expense | 2.79 | 12.12 | 18.43 | 18.62 |
| General And Administrative Expense | 17.72 | 20.59 | 23.05 | 28.29 |
| Other Gand A | 17.72 | 20.59 | 23.05 | 28.29 |
| Operating Revenue | 1.53 | 21.25 | 47.54 | 44.64 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc.this co. | FENC | - | - | - | -27.5% | - |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M |
| - |
| 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |